Notably, a 51-year-old woman with fulvestrant-resistant, ER+/PR+/HER2-breast cancer that had metastasized to the bone treated at the 40 mg dose level experienced a dramatic decline in FDG activity of her disease by PET CT imaging after 2 cycles of treatment (Fig. 1). The gene discussed is ESR1; the disease is breast cancer.